HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $59

Benzinga Newsdesk www.benzinga.com Neutral 47.3%

Neg 0% Neu 47.3% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $60 to $59.